Roche Korea, "No decision has been made to resupply Madopar

Discussion with the Ministry of Health and Welfare to extend the deferment of benefit deletion

Roche Korea recently announced that it has no plans to resupply Madopar, a Parkinson's disease treatment for which the grace period for the deletion of benefits was recently extended.

 

It is explained that the headquarters did not make a decision to resupply, and that no agreement was signed with any organization for resupply.

 

The extension of the grace period for deletion of benefits was carried out in consultation with the Ministry of Health and Welfare, and it is explained that there is no plan to resupply Madopar during that period.

 

An official from Roche Korea said in a phone call on the 4th.

 

announced its withdrawal from the country in January by voluntarily withdrawing Madopar's license.

 

Patients with Parkinson's disease are urging the resupply of Madopar, urging Myungdopar, which is the only generic drug with the same drug, to have significant side effects.

 

The Ministry of Health and Welfare has also opened the door to resupply, saying that it is possible to negotiate a price increase through the upper limit adjustment system, and some have reported that the Parkinson's Association and Roche Korea have agreed to resupply Madopar.

 

Roche Korea said that the agreement for Madopar was not true.

 

A company official explained, "The head office has not made any decision regarding the resupply of Madopar." However, he explained that the reason why the grace period for deleting benefits was extended was because there was a consultation with the Ministry of Health and Welfare.

 

The official explained, "After checking the Madopar inventory, we found that there was still a lot left, and in consultation with the Ministry of Health and Welfare, we extended the grace period for the deletion of benefits to prevent patients from suffering economic damage." The grace period for deleting Madopar benefits was extended by 4 months to a total of 10 months.

 

Normally, the grace period for deleting benefits is up to six months, but it was extended by four months under the authority of the Ministry of Health and Welfare.

 

As a grace period was granted, some said that the Ministry of Health and Welfare and Roche had confirmed the resupply of Madopar and extended the grace period.

 

There is criticism that it is giving preferential treatment to original drugs that have voluntarily withdrawn from the market.

 

In addition, the generic industry argues that if the government follows the issue of resupplying the original, the reliability of generics will decrease.